Clinical Trial Update: A Study to Evaluate Sotigalimab (APX005M) in Subjects With Unresectable or Metastatic Melanoma [Phase 2]

View source ↗

Summary

Phase 2 study evaluating sotigalimab (APX005M) in unresectable or metastatic melanoma has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Unresectable Melanoma

Drugs mentioned

• sotigalimab (sotigalimab)

Snippet

Sponsor: Apexigen America, Inc. | Conditions: Unresectable Melanoma, Metastatic Melanoma | Phase 2 | Status: TERMINATED | Results posted: 2023-12-22